The detection of the EGFR T790M mutation has been reported as associated with resistance to EGFR tyrosine kinase inhibitor in NSCLC [138], while the role of circulating RAS mutations assessment in plasma has been depicted for colorectal cancer and melanoma for both the prediction of response to therapy and early detection of resistance [139,140]. The gene discussed is EGFR; the disease is colorectal cancer.